Idenix Pharmaceuticals

About Idenix Pharmaceuticals

Idenix Pharmaceuticals, Inc. operated as a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for treating human viral diseases. The company was founded in May 1998 by Dr. Jean-Pierre Sommadossi, who brought over 30 years of experience in the biotech industry to the venture. Before his entrepreneurial career, Dr. Sommadossi was a Professor of Pharmacology, Toxicology, and Clinical Pharmacology at the University of Alabama at Birmingham, and his scientific background heavily influenced the company's direction.

The company's business model was centered on research and development, aiming to build a robust pipeline of antiviral drug candidates. Idenix's primary focus was on developing treatments for Hepatitis C (HCV), Hepatitis B (HBV), and HIV. Revenue and operational funding were generated through strategic collaborations and partnerships with major pharmaceutical companies. A significant milestone was the 2003 collaboration with Novartis Pharma AG, which included the development and commercialization of product candidates and a substantial equity investment by Novartis. This partnership led to the co-development and launch of telbivudine (Tyzeka/Sebivo) for the treatment of hepatitis B.

Idenix's core product development strategy revolved around its expertise in nucleoside and nucleotide chemistry to create small molecule therapeutics. At the time of its acquisition, the company had three promising HCV drug candidates in clinical development: two nucleotide prodrugs, IDX21437 and IDX21459, and an NS5A inhibitor, samatasvir. These candidates were being evaluated for use in combination regimens to create more effective, all-oral treatments for various HCV genotypes. The company maintained research and development operations in Cambridge, Massachusetts, and Montpellier, France.

A pivotal moment in the company's history occurred in June 2014, when Merck & Co. announced a definitive agreement to acquire Idenix for approximately $3.85 billion. Merck's strategic interest was to bolster its own pipeline of hepatitis C treatments and to leverage Idenix's portfolio to develop a highly effective, pan-genotypic, once-daily oral regimen. The acquisition was completed in August 2014, marking the conclusion of Idenix's journey as an independent entity and integrating its assets and expertise into Merck's global health operations.